TTM
31.7%
YoY change
+4.83pp
Trough year (1998)
-7.5%
Peak year (2025)
32.3%
Latest annual
32.3%
FCF Margin history chart for ResMed (RMD) from 1993 to 2025
Latest: 32.3%
FCF Margin change chart for ResMed (RMD) from 1993 to 2025
Latest: +4.83pp
FCF Margin history table for ResMed (RMD) from 1993 to 2025
| 2025 | 32.3% | +4.83pp | ||
| 2024 | 27.5% | +14.21pp | ||
| 2023 | 13.2% | +7.79pp | ||
| 2022 | 5.5% | -13.94pp | ||
| 2021 | 19.4% | -4.16pp | ||
| 2020 | 23.5% | +8.90pp | ||
| 2019 | 14.6% | -3.88pp | ||
| 2018 | 18.5% | +1.95pp | ||
| 2017 | 16.6% | -9.54pp | ||
| 2016 | 26.1% | +7.57pp | ||
| 2015 | 18.5% | -1.41pp | ||
| 2014 | 19.9% | -1.92pp | ||
| 2013 | 21.9% | -1.67pp | ||
| 2012 | 23.5% | +6.79pp | ||
| 2011 | 16.7% | +5.16pp | ||
| 2010 | 11.6% | -1.95pp | ||
| 2009 | 13.5% | +6.11pp | ||
| 2008 | 7.4% | +5.54pp | ||
| 2007 | 1.9% | +2.50pp | ||
| 2006 | -0.6% | -7.99pp | ||
| 2005 | 7.4% | +1.69pp | ||
| 2004 | 5.7% | -6.61pp | ||
| 2003 | 12.3% | +8.65pp | ||
| 2002 | 3.7% | +2.32pp | ||
| 2001 | 1.3% | -2.22pp | ||
| 2000 | 3.6% | +8.41pp | ||
| 1999 | -4.9% | +2.67pp | ||
| 1998 | -7.5% | -18.70pp | ||
| 1997 | 11.2% | +5.40pp | ||
| 1996 | 5.8% | +10.46pp | ||
| 1995 | -4.7% | -14.03pp | ||
| 1994 | 9.4% | +0.26pp | ||
| 1993 | 9.1% | — |
- 202532.3%+4.83pp
- 202427.5%+14.21pp
- 202313.2%+7.79pp
- 20225.5%-13.94pp
- 202119.4%-4.16pp
- 202023.5%+8.90pp
- 201914.6%-3.88pp
- 201818.5%+1.95pp
- 201716.6%-9.54pp
- 201626.1%+7.57pp
- 201518.5%-1.41pp
- 201419.9%-1.92pp
- 201321.9%-1.67pp
- 201223.5%+6.79pp
- 201116.7%+5.16pp
- 201011.6%-1.95pp
- 200913.5%+6.11pp
- 20087.4%+5.54pp
- 20071.9%+2.50pp
- 2006-0.6%-7.99pp
- 20057.4%+1.69pp
- 20045.7%-6.61pp
- 200312.3%+8.65pp
- 20023.7%+2.32pp
- 20011.3%-2.22pp
- 20003.6%+8.41pp
- 1999-4.9%+2.67pp
- 1998-7.5%-18.70pp
- 199711.2%+5.40pp
- 19965.8%+10.46pp
- 1995-4.7%-14.03pp
- 19949.4%+0.26pp
- 19939.1%—
FCF Margin values are taken from ResMed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About FCF Margin at ResMed (RMD)
According to ResMed's latest reported financial statements, the company's latest reported free cash flow margin is 31.7%. Free cash flow margin is free cash flow divided by revenue — the share of each sales dollar that converts into cash after capital expenditures. Because free cash flow cannot be inflated by non-cash accounting, FCF margin is a clean read on how efficiently a business turns revenue into deployable cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, ResMed (RMD) reported free cash flow margin of 32.29% – expanded 4.8 percentage points year-over-year.
The record annual free cash flow margin stands at 32.29%, reached in 2025; the historical low of -7.52% was recorded in 1998.
ResMed FCF Margin by Year
ResMed FCF Margin 2025: 32.3%
2025's free cash flow margin for ResMed came in at 32.29%, expanded 4.8 percentage points from 2024. This figure represents the highest annual value in the available history.
ResMed FCF Margin 2024: 27.5%
ResMed posted free cash flow margin of 27.46% in 2024, expanded 14.2 percentage points from 2023.
ResMed FCF Margin 2023: 13.2%
In 2023, ResMed reported free cash flow margin of 13.24%, expanded 7.8 percentage points from 2022.
ResMed FCF Margin 2022: 5.5%
ResMed free cash flow margin in 2022 was 5.45%, contracted 13.9 percentage points from 2021.
ResMed FCF Margin 2021: 19.4%
ResMed free cash flow margin in 2021 was 19.39%.
See more financial history for ResMed (RMD).
Sector peers by FCF Margin
Healthcare peers of ResMed (RMD), ranked by their latest free cash flow margin
| 33.2% | |
| 23.1% | |
| 21.5% | |
| 18.8% | |
| 18.4% | |
| 15.1% | |
| 9.4% | |
| 4.4% |
- 33.2%
- 23.1%
- 21.5%
- 18.8%
- 15.1%
Frequently asked questions
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation